Liquidia (LQDA) Share-based Compensation Growth (1y) (2021 - 2026)
Liquidia (LQDA) Share-based Compensation Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 5.26% |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn | -36.59% |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn | -0.11% |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | -49.74% |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn | -18.06% |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn | 23.11% |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | -65.00% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - | - |
| 10 | Liquidia | 6.40 Bn | 6.12 Bn | 160.92 Mn | 49.64% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 49.64% |
| Mar 31, 2026 | 23.92% |
| Dec 31, 2025 | 43.29% |
| Sep 30, 2025 | 61.81% |
| Jun 30, 2025 | 58.51% |
| Mar 31, 2025 | 64.41% |
| Dec 31, 2024 | 97.14% |
| Sep 30, 2024 | 96.26% |
| Jun 30, 2024 | 74.95% |
| Mar 31, 2024 | 77.27% |
| Dec 31, 2023 | 40.32% |
| Sep 30, 2023 | 50.91% |
| Jun 30, 2023 | 51.73% |
| Mar 31, 2023 | 60,879.69% |
| Dec 31, 2022 | -52.46% |
| Sep 30, 2022 | 34.64% |
| Jun 30, 2022 | 72.82% |
| Mar 31, 2022 | 461.74% |
| Dec 31, 2021 | 280.15% |
| Sep 30, 2021 | 13.23% |